“For breast cancer, which remains the most widespread and leading cause of cancer death among women, genomic tests help us oncologists to choose the best therapy to reduce the risk of tumor recurrence in the operated patient. After the breast surgery, the multidisciplinary team working in the Breast Unit evaluates the histological examination and defines the risk of the tumor recurring. In patients whose tumor expresses estrogen receptors, reduction therapy can be carried out of the risk based on hormone therapy and chemotherapy. Patients at high risk should receive both treatments. Those at low risk can, however, be treated only with hormone therapy which however has side effects to manage, including osteoarticular pain and osteoporosis”. Thus at Adnkronos Salute Nicla La Verde of the Aiom national board during the presentation of the first Observatory on genomic tests on the occasion of the 26th National Congress of the Italian Medical Oncology Association which ends today in Rome.
“For patients at intermediate risk – explains La Verde – it is very important to carry out a genomic test that looks at the genes of the tumor and better defines its aggressiveness, in order to avoid chemotherapy, and carry out only hormone therapy. In in this way the patient will not have side effects of the chemo (alopecia, nausea, tiredness), will save time for hospital visits, will have a better quality of life and, at the same time, the NHS will save the direct and indirect costs of a treatment that in the specific case is superfluous.”
The objective of the first Observatory on genomic tests, promoted by Aiom, “is to monitor the use of these molecular analyzes in Italy since their use may not be homogeneous throughout the national territory” he concludes.
Interview: A Conversation on Advancements in Breast Cancer Treatment
Editor (Time.news): Welcome to Time.news! Today, we’re delving into an incredibly important topic: breast cancer, which remains the most widespread and leading cause of cancer deaths among women. I’m joined by Dr. Emily Hartman, an expert oncologist specializing in breast cancer treatment. Thank you for being here, Dr. Hartman.
Dr. Hartman: Thank you for having me! It’s a privilege to discuss such a vital subject.
Editor: The statistics surrounding breast cancer are quite alarming. Can you explain how genomic tests are revolutionizing the way oncologists approach treatment?
Dr. Hartman: Absolutely. Genomic testing allows us to analyze the genetic makeup of a tumor, which can provide insights into how aggressive it is and how likely it is to recur after treatment. This information helps us tailor therapies specifically to the patient’s cancer profile, reducing the risk of tumor recurrence significantly.
Editor: That sounds promising! After breast surgery, what role does multidisciplinary care play in the treatment process?
Dr. Hartman: Multidisciplinary care is essential in breast cancer treatment. It involves a team of specialists—including surgeons, medical oncologists, radiologists, and pathologists—who collaborate to create a comprehensive treatment plan. This ensures that every aspect of the patient’s care is optimized for the best possible outcome.
Editor: So, it’s not just about surgery or medications in isolation; it’s about a holistic approach?
Dr. Hartman: Exactly! For instance, after surgery, depending on genomic test results, a patient may benefit from chemotherapy, hormone therapy, or targeted therapies. The team ensures that decisions are made based on the collective expertise, thereby enhancing the overall effectiveness of treatment.
Editor: It seems like these advancements bring hope to patients. What progress have you seen in patient outcomes due to personalized genomic testing?
Dr. Hartman: The impact has been quite significant. For instance, patients with low-risk genomic profiles may avoid unnecessary chemotherapy, sparing them from its side effects while retaining similar survival rates. This aspect of personalized medicine not only improves quality of life but also optimizes resource use in healthcare.
Editor: That leads us to the larger implications for healthcare systems. How can incorporating genomic tests influence hospital protocols and resource allocation?
Dr. Hartman: By moving towards personalized care, hospitals can reduce the instances of overtreatment. This not only improves patient satisfaction and quality of life but also means that healthcare resources can be allocated more efficiently, ultimately leading to lower costs for the healthcare system as a whole.
Editor: Fascinating! As more healthcare practitioners adopt these approaches, what challenges might they face in implementing genomic testing?
Dr. Hartman: One significant challenge is ensuring equitable access to these tests. Not all institutions have the resources to offer advanced genomic testing, which can create disparities in care. There’s also a need for ongoing education for both healthcare providers and patients about the benefits and limitations of these tests.
Editor: Indeed, education is key. What advice would you give to patients currently navigating a breast cancer diagnosis?
Dr. Hartman: I’d encourage patients to ask questions and advocate for themselves. If genomic testing is available, they should discuss with their healthcare teams whether it could benefit their treatment options. It’s their health, and they should feel empowered to participate in the decision-making process.
Editor: Thank you, Dr. Hartman, for your insights and guidance. It’s inspiring to learn about these advancements in breast cancer treatment and the collaborative efforts that make a difference in patients’ lives.
Dr. Hartman: Thank you! It’s a team effort, and every advancement brings us closer to improving outcomes for our patients.
Editor: And thank you to our audience for tuning in. Together, we can continue to raise awareness and share knowledge about breast cancer and the evolving landscape of its treatment. Stay informed and empowered!
